vs

Side-by-side financial comparison of ACCESS Newswire Inc. (ACCS) and BioAge Labs, Inc. (BIOA). Click either name above to swap in a different company.

ACCESS Newswire Inc. is the larger business by last-quarter revenue ($5.8M vs $3.1M, roughly 1.9× BioAge Labs, Inc.). ACCESS Newswire Inc. runs the higher net margin — -9.9% vs -842.9%, a 832.9% gap on every dollar of revenue.

PR Newswire is a distributor of press releases headquartered in Chicago. The service was created in 1954 to allow companies to electronically send press releases to news organizations, using teleprinters at first. The founder, Herbert Muschel, operated the service from his house in Manhattan for approximately 15 years. The business was eventually sold to Western Union and then United Newspapers of London. In December 2015, Cision Inc. announced it would acquire the company. On January 1, 2021...

Altos Labs, Inc. is an American biotechnology research company. Altos Labs' goal is to develop life extension therapies that can halt or reverse the human aging process. Specialized cell therapies based on induced pluripotent stem cells are to be developed for this purpose. Russian-born technology businessman Yuri Milner, along with investors including Jeff Bezos, funded the company in 2021, operations started in 2022.

ACCS vs BIOA — Head-to-Head

Bigger by revenue
ACCS
ACCS
1.9× larger
ACCS
$5.8M
$3.1M
BIOA
Higher net margin
ACCS
ACCS
832.9% more per $
ACCS
-9.9%
-842.9%
BIOA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACCS
ACCS
BIOA
BIOA
Revenue
$5.8M
$3.1M
Net Profit
$-576.0K
$-25.9M
Gross Margin
77.4%
Operating Margin
-13.1%
-923.4%
Net Margin
-9.9%
-842.9%
Revenue YoY
-0.5%
Net Profit YoY
94.4%
EPS (diluted)
$-0.16
$-0.72

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACCS
ACCS
BIOA
BIOA
Q4 25
$5.8M
$3.1M
Q3 25
$5.7M
$2.1M
Q2 25
$5.6M
$2.4M
Q1 25
$5.5M
$1.5M
Q4 24
$5.8M
Q3 24
$5.6M
$0
Q2 24
$6.0M
Q1 24
$5.6M
Net Profit
ACCS
ACCS
BIOA
BIOA
Q4 25
$-576.0K
$-25.9M
Q3 25
$-45.0K
$-20.2M
Q2 25
$-475.0K
$-21.6M
Q1 25
$5.4M
$-12.9M
Q4 24
$-10.2M
Q3 24
$-466.0K
$-23.4M
Q2 24
$7.0K
Q1 24
$-139.0K
Gross Margin
ACCS
ACCS
BIOA
BIOA
Q4 25
77.4%
Q3 25
74.6%
Q2 25
76.2%
Q1 25
78.0%
Q4 24
75.2%
Q3 24
75.0%
Q2 24
77.2%
Q1 24
75.1%
Operating Margin
ACCS
ACCS
BIOA
BIOA
Q4 25
-13.1%
-923.4%
Q3 25
-3.2%
-1126.6%
Q2 25
-4.4%
-1027.0%
Q1 25
-12.4%
-1133.4%
Q4 24
-245.8%
Q3 24
-10.7%
Q2 24
-8.8%
Q1 24
-15.5%
Net Margin
ACCS
ACCS
BIOA
BIOA
Q4 25
-9.9%
-842.9%
Q3 25
-0.8%
-982.0%
Q2 25
-8.5%
-894.0%
Q1 25
98.4%
-891.0%
Q4 24
-175.0%
Q3 24
-8.3%
Q2 24
0.1%
Q1 24
-2.5%
EPS (diluted)
ACCS
ACCS
BIOA
BIOA
Q4 25
$-0.16
$-0.72
Q3 25
$-0.01
$-0.56
Q2 25
$-0.12
$-0.60
Q1 25
$1.40
$-0.36
Q4 24
$-2.66
Q3 24
$-0.12
$-6.70
Q2 24
$0.00
Q1 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACCS
ACCS
BIOA
BIOA
Cash + ST InvestmentsLiquidity on hand
$3.0M
$281.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$30.3M
$272.1M
Total Assets
$42.0M
$294.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACCS
ACCS
BIOA
BIOA
Q4 25
$3.0M
$281.1M
Q3 25
$3.3M
$285.8M
Q2 25
$297.3M
Q1 25
$320.5M
Q4 24
$4.1M
Q3 24
$334.5M
Q2 24
Q1 24
Total Debt
ACCS
ACCS
BIOA
BIOA
Q4 25
Q3 25
Q2 25
Q1 25
$7.1M
Q4 24
Q3 24
$9.9M
Q2 24
Q1 24
Stockholders' Equity
ACCS
ACCS
BIOA
BIOA
Q4 25
$30.3M
$272.1M
Q3 25
$30.8M
$277.5M
Q2 25
$30.7M
$294.8M
Q1 25
$30.9M
$313.2M
Q4 24
$25.2M
Q3 24
$35.3M
$313.7M
Q2 24
$35.4M
Q1 24
$35.2M
Total Assets
ACCS
ACCS
BIOA
BIOA
Q4 25
$42.0M
$294.9M
Q3 25
$44.0M
$305.1M
Q2 25
$45.6M
$322.1M
Q1 25
$47.3M
$343.8M
Q4 24
$50.6M
Q3 24
$61.7M
$337.4M
Q2 24
$62.8M
Q1 24
$64.4M
Debt / Equity
ACCS
ACCS
BIOA
BIOA
Q4 25
Q3 25
Q2 25
Q1 25
0.02×
Q4 24
Q3 24
0.03×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACCS
ACCS
BIOA
BIOA
Operating Cash FlowLast quarter
$258.0K
$-28.3M
Free Cash FlowOCF − Capex
$-28.4M
FCF MarginFCF / Revenue
-921.5%
Capex IntensityCapex / Revenue
0.0%
3.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-82.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACCS
ACCS
BIOA
BIOA
Q4 25
$258.0K
$-28.3M
Q3 25
$-582.0K
$-16.0M
Q2 25
$135.0K
$-20.0M
Q1 25
$747.0K
$-17.4M
Q4 24
$866.0K
Q3 24
$1.5M
Q2 24
$-190.0K
Q1 24
$986.0K
Free Cash Flow
ACCS
ACCS
BIOA
BIOA
Q4 25
$-28.4M
Q3 25
$-590.0K
$-16.1M
Q2 25
$-20.1M
Q1 25
$735.0K
$-17.8M
Q4 24
Q3 24
$1.5M
Q2 24
Q1 24
$970.0K
FCF Margin
ACCS
ACCS
BIOA
BIOA
Q4 25
-921.5%
Q3 25
-10.3%
-782.2%
Q2 25
-834.5%
Q1 25
13.4%
-1226.0%
Q4 24
Q3 24
26.5%
Q2 24
Q1 24
17.4%
Capex Intensity
ACCS
ACCS
BIOA
BIOA
Q4 25
0.0%
3.6%
Q3 25
0.1%
1.1%
Q2 25
0.0%
6.6%
Q1 25
0.2%
29.4%
Q4 24
0.0%
Q3 24
0.1%
Q2 24
0.0%
Q1 24
0.3%
Cash Conversion
ACCS
ACCS
BIOA
BIOA
Q4 25
Q3 25
Q2 25
Q1 25
0.14×
Q4 24
Q3 24
Q2 24
-27.14×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACCS
ACCS

Cost To Deliver Products$3.1M54%
Employee Costs$1.7M29%
Other$1.0M17%

BIOA
BIOA

Segment breakdown not available.

Related Comparisons